Fatigue in adult XXXX with primary @entity3039 .

@entity1 @entity548 @entity1295 @entity230 @entity3039 @entity25
BACKGROUND:    @entity1 with primary @entity3039 ( @entity3039 ) commonly describe symptoms of @entity1295 . However, hematologists rarely consider @entity1295 a manifestation of @entity3039 . OBJECTIVES:     To document the prevalence of @entity1295 among @entity1 with @entity3039 and to determine the @entity1 characteristics that are associated with @entity1295 .     Using a cross-sectional design, we surveyed 1871 members of the UK @entity3039 Support Association [585 (31%) responded], and 93 @entity1 enrolled in the Oklahoma (US) @entity3039 Registry [68 (73%) responded] with questions about their @entity3039 and with validated symptom assessment scales for @entity1295 , @entity25 , and orthostatic symptoms. RESULTS:     The prevalence of @entity1295 among both UK (39%) and US (22%) @entity1 was significantly greater than expected compared with normal subjects (P<0.0001 and P<0.0001 respectively). In univariate analysis of the combined cohorts, @entity1295 was associated with a platelet count <100000/ L, treatment with @entity230 , @entity548 symptoms, presence of other medical conditions, @entity25 , and orthostatic symptoms. Fatigue was not associated with age, gender, duration of @entity3039 , or splenectomy status. Multivariate analysis of the combined cohorts was stratified for the presence or absence of @entity548 symptoms. Among 107 @entity1 with @entity548 symptoms, @entity1295 was independently associated with a platelet count <100000/ L and female gender. Among 491 @entity1 without @entity548 symptoms, @entity1295 was independently associated with a platelet count <30000/ L, presence of other medical conditions, @entity25 , and orthostatic symptoms. CONCLUSIONS:     Fatigue is a common symptom among @entity1 with @entity3039 . These data provide the basis for future studies to define the clinical importance of @entity1295 in @entity3039 .
